Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Catalent Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Catalent kazanç ve gelirin sırasıyla yıllık 98.4% ve 6.8% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 104.1% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 9% olacağı tahmin edilmektedir.

Anahtar bilgiler

98.4%

Kazanç büyüme oranı

104.1%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	23.8%
Gelir büyüme oranı	6.8%
Gelecekteki özkaynak getirisi	9.0%
Analist kapsamı	Good
Son güncelleme	27 Sep 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Catalent, Inc.'s (NYSE:CTLT) Share Price Not Quite Adding Up

Aug 30

Are Investors Undervaluing Catalent, Inc. (NYSE:CTLT) By 24%?

Jul 23

Beyond Elevidys: Unveiling The Competitive Landscape Of Duchenne's Muscular Dystrophy

Jun 25

Catalent to make Sarepta Therapeutics' muscle wasting gene therapy under supply deal

Jan 05

An Intrinsic Calculation For Catalent, Inc. (NYSE:CTLT) Suggests It's 27% Undervalued

Dec 27

Humanigen to pay Catalent Pharma $12M to settle supply agreement dispute

Dec 22

Catalent falls after new short call from Glasshouse Research

Dec 08

Catalent Q1 2023 Earnings Preview

Oct 31

These 4 Measures Indicate That Catalent (NYSE:CTLT) Is Using Debt Extensively

Oct 26

Catalent: Charting A Post-Covid Future

Oct 19

Kazanç ve Gelir Büyüme Tahminleri

NYSE:CTLT - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2027	5,380	361	N/A	N/A	1
6/30/2026	5,056	152	N/A	N/A	8
6/30/2025	4,692	41	39	482	9
6/30/2024	4,381	-1,043	-59	268	N/A
3/31/2024	4,135	-1,176	-123	250	N/A
12/31/2023	4,098	-1,302	-263	174	N/A
9/30/2023	4,223	-1,015	-235	276	N/A
6/30/2023	4,263	-256	-322	254	N/A
3/31/2023	4,495	21	-563	127	N/A
12/31/2022	4,731	389	-371	329	N/A
9/30/2022	4,799	399	-471	184	N/A
6/30/2022	4,802	483	-221	439	N/A
3/31/2022	4,703	485	-110	504	N/A
12/31/2021	4,483	561	-183	441	N/A
9/30/2021	4,177	544	-244	446	N/A
6/30/2021	3,998	529	-253	433	N/A
3/31/2021	3,757	494	-188	471	N/A
12/31/2020	3,465	289	-135	518	N/A
9/30/2020	3,275	250	22	565	N/A
6/30/2020	3,094	173	-26	440	N/A
3/31/2020	2,872	104	-37	356	N/A
12/31/2019	2,729	124	20	309	N/A
9/30/2019	2,631	138	-22	232	N/A
6/30/2019	2,518	132	30	248	N/A
3/31/2019	2,478	149	75	263	N/A
12/31/2018	2,488	136	108	283	N/A
9/30/2018	2,471	65	160	332	N/A
6/30/2018	2,463	84	198	375	N/A
3/31/2018	2,395	63	N/A	371	N/A
12/31/2017	2,300	70	N/A	380	N/A
9/30/2017	2,177	109	N/A	335	N/A
6/30/2017	2,075	110	N/A	300	N/A
3/31/2017	1,991	106	N/A	233	N/A
12/31/2016	1,896	91	N/A	180	N/A
9/30/2016	1,867	104	N/A	159	N/A
6/30/2016	1,848	112	N/A	155	N/A
3/31/2016	1,826	207	N/A	199	N/A
12/31/2015	1,835	228	N/A	243	N/A
9/30/2015	1,836	244	N/A	257	N/A
6/30/2015	1,831	212	N/A	172	N/A
3/31/2015	1,840	86	N/A	180	N/A
12/31/2014	1,847	62	N/A	138	N/A
9/30/2014	1,832	-3	N/A	113	N/A
6/30/2014	1,828	19	N/A	178	N/A
3/31/2014	1,813	2	N/A	148	N/A
12/31/2013	1,807	-20	N/A	152	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: CTLT önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.5% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: CTLT önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: CTLT önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: CTLT şirketinin gelirinin (yıllık 6.8% ) US pazarından (yıllık 8.7% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: CTLT şirketinin gelirinin (yıllık 6.8% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: CTLT 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 9 %).

Catalent Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target increased by 15% to US$63.50

Catalent, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2024

Catalent, Inc. Updates Revenue Guidance for the Full Year of 2023

Price target decreased by 7.6% to US$63.17

Catalent, Inc. Reduces Revenue Guidance for the Fiscal Year 2023

Consensus EPS estimates fall by 10%

Recent updates

Catalent, Inc. announced delayed annual 10-K filing

Full year 2024 earnings: EPS misses analyst expectations

Catalent, Inc.'s (NYSE:CTLT) Share Price Not Quite Adding Up

New minor risk - Insider selling

President recently sold US$534k worth of stock

President notifies of intention to sell stock

Are Investors Undervaluing Catalent, Inc. (NYSE:CTLT) By 24%?

Beyond Elevidys: Unveiling The Competitive Landscape Of Duchenne's Muscular Dystrophy

Now 20% undervalued after recent price drop

Price target increased by 15% to US$63.50

Insufficient new directors

Catalent, Inc. announced delayed 10-Q filing

Insufficient new directors

Catalent - Novo Holdings Merger: Attractive Spread

Novo Holdings A/S entered into an agreement to acquire Catalent, Inc. (NYSE:CTLT) from Elliott Investment Management L.P. and other for $11.7 million.

Novo Holdings A/S entered into an agreement to acquire Catalent, Inc. (NYSE:CTLT) from Elliott Investment Management L.P. and other for $11.7 million.

Catalent, Inc. to Report Q2, 2024 Results on Feb 09, 2024

Catalent, Inc. Announces Executive Changes

Catalent, Inc., Annual General Meeting, Jan 25, 2024

Catalent: Debt Remains An Overhang

Catalent, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2024

Catalent, Inc. announced delayed 10-Q filing

Catalent, Inc. to Report Q1, 2024 Results on Nov 15, 2023

Catalent Remains Overvalued

Catalent, Inc. Appoints David McErlane as Group President of Catalent’s Biologics segment, Effective September 25, 2023

Catalent Receives NYSE Notice Regarding Late Form 10-K Filing

Catalent, Inc. Appoints Steven Barg as A Member of the Board of Directors

Catalent, Inc. announced delayed annual 10-K filing

Full year 2023 earnings: EPS misses analyst expectations

Catalent, Inc. Announces Board Changes

Catalent, Inc. to Report Q4, 2023 Results on Aug 29, 2023

Calculating The Intrinsic Value Of Catalent, Inc. (NYSE:CTLT)

Insufficient new directors

Catalent, Inc. Announces Executive Changes

Catalent: Myriad Issues To Fix

Catalent, Inc.(NYSE:CTLT) dropped from Russell 1000 Growth Index

Catalent, Inc. Appoints Matti Masanovich as Senior Vice President, Effective July 5, 2023

Catalent Regains Compliance with NYSE Continued Listing Standards

Catalent, Inc. Reports Impairment Results for the Quarter Ended March 31, 2023

New minor risk - Earnings quality

Catalent, Inc. Updates Revenue Guidance for the Full Year of 2023

Catalent, Inc. announced delayed 10-Q filing

Price target decreased by 7.6% to US$63.17

Catalent, Inc. Reduces Revenue Guidance for the Fiscal Year 2023

Now 30% undervalued after recent price drop

Catalent (NYSE:CTLT) Has A Somewhat Strained Balance Sheet

Insider recently sold US$72k worth of stock

Investor sentiment improves as stock rises 15%

Now 22% undervalued after recent price drop

Consensus EPS estimates fall by 10%

Investor sentiment deteriorates as stock falls 29%

A Look At The Intrinsic Value Of Catalent, Inc. (NYSE:CTLT)

Catalent Appoints Joseph A. Ferraro as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary

Price target increased by 11% to US$82.36

Catalent, Inc. Reiterates Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Danaher Reportedly Expresses Takeover Interest in Catalent

Investor sentiment improves as stock rises 27%

Why did Catalent stock soar today? Potential takeover by Danaher

We Think Catalent (NYSE:CTLT) Is Taking Some Risk With Its Debt

Catalent, Inc. to Report Q2, 2023 Results on Feb 07, 2023

Catalent, Inc. Announces the Appointment of Ricardo Zayas as Senior Vice President, Operations, Biologics North America

Catalent to make Sarepta Therapeutics' muscle wasting gene therapy under supply deal

An Intrinsic Calculation For Catalent, Inc. (NYSE:CTLT) Suggests It's 27% Undervalued

Humanigen to pay Catalent Pharma $12M to settle supply agreement dispute

Catalent, Inc. Announces Director Changes

Catalent falls after new short call from Glasshouse Research

Now 23% undervalued after recent price drop

Investor sentiment improved over the past week